Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 12/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | GRK6 | P43250 | 1/20 | 0.38 |
| ▸ | NOS3 | P29474 | 1/20 | 0.37 |
| ▸ | NOS1 | P29475 | 1/20 | 0.37 |
| ▸ | NOS2 | P35228 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16515861 | 0.84 | CETP (0.42) | CETPCYP2A6PSMB8HDAC6GRK6 | |
| SCHEMBL5229436 | 0.84 | PSMB8 (0.44) | CETPCYP2A6PSMB8HDAC6GRK6 | |
| SCHEMBL30358385 | 0.80 | CETP (0.44) | CETPCYP2A6PSMB8HDAC6GRK6 | |
| SCHEMBL103936 | 0.79 | GRK6 (0.40) | CETPCYP2A6PSMB8HDAC6GRK6 | |
| SCHEMBL12778294 | 0.78 | CYP2A6 (0.44) | CETPCYP2A6PSMB8HDAC6NOS3 | |
| SCHEMBL31119214 | 0.76 | LMNA (0.58) | CETPCYP2A6PSMB8HDAC6NOS3 | |
| SCHEMBL11443247 | 0.76 | LMNA (0.58) | CETPCYP2A6PSMB8HDAC6NOS3 | |
| SCHEMBL14432506 | 0.75 | SOS1 (0.58) | CETP | |
| SCHEMBL17942214 | 0.75 | CYP2A6 (0.44) | CETPCYP2A6PSMB8HDAC6NOS3 | |
| SCHEMBL2711759 | 0.75 | CYP2A6 (0.44) | CETPCYP2A6PSMB8HDAC6NOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100168167-A1 | Piperidinones Useful in the Treatment of Inflammation | BIOLIPOX AB (SE) | 2010-07-01 | — | — | US | disclosed |
| EP-2134686-A1 | PIPERIDINONES USEFUL IN THE TREATMENT OF INFLAMMATION | Biolipox AB (SE) | 2009-12-23 | — | — | EP | disclosed |
| WO-2008110793-A1 | PIPERIDINONES USEFUL IN THE TREATMENT OF INFLAMMATION | BIOLIPOX AB (SE) | 2008-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168167-A1 | Piperidinones Useful in the Treatment of Inflammation | ARG1, ARG2, PRMT1 | CETP 3876/4885CYP2A6 2141/4885PSMB8 3657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.